Prognostic factors among patients with Shiga toxin-producing Escherichia coli hemolytic uremic syndrome: A retrospective cohort study using a nationwide inpatient database in Japan

J Infect Chemother. 2023 Jun;29(6):610-614. doi: 10.1016/j.jiac.2023.02.016. Epub 2023 Mar 4.

Abstract

Introduction: Shiga toxin-producing Escherichia coli (STEC) causes hemorrhagic colitis and hemolytic uremic syndrome (STEC-HUS). Understanding its prognostic factors is essential for immediate interventions. We examined early-phase unfavorable prognostic factors among patients with STEC-HUS using a nationwide database.

Material and methods: This is a retrospective cohort study to analyze practice patterns and identify prognostic factors among patients with STEC-HUS. We used the Diagnosis Procedure Combination Database, which includes approximately half of the acute-care hospitalized patients in Japan. We enrolled patients who were hospitalized for STEC-HUS from July 2010 to March 2020. The composite unfavorable outcome included in-hospital death, mechanical ventilation, dialysis, and rehabilitation at discharge. Unfavorable prognostic factors were assessed using a multivariable logistic regression model.

Results: We included 615 patients with STEC-HUS (median age, 7 years). Of them, 30 (4.9%) patients had acute encephalopathy and 24 (3.9%) died within 3 months of admission. Unfavorable composite outcome was observed in 124 (20.2%) patients. Significant unfavorable prognostic factors were age of 18 years or older, methylprednisolone pulse therapy, antiepileptic drug administration, and respiratory support within 2 days of admission.

Discussion: Patients requiring early steroid pulse therapy, antiepileptic drugs, and respiratory support were considered to be in poor general condition; such patients should receive aggressive intervention to avoid worse outcomes.

Keywords: Hemolytic uremic syndrome; Prognostic factors; Shiga toxin-producing Escherichia coli.

MeSH terms

  • Adolescent
  • Child
  • Escherichia coli Infections* / diagnosis
  • Escherichia coli Infections* / drug therapy
  • Escherichia coli Infections* / epidemiology
  • Hemolytic-Uremic Syndrome* / diagnosis
  • Hemolytic-Uremic Syndrome* / epidemiology
  • Hemolytic-Uremic Syndrome* / therapy
  • Hospital Mortality
  • Humans
  • Inpatients
  • Japan / epidemiology
  • Prognosis
  • Retrospective Studies
  • Shiga-Toxigenic Escherichia coli*